Although is clear that exposure to high dosage levels of some phthalates delays the onset of puberty in the male rat, it has been hypothesized that low levels of di(2-ethylhexyl) phthalate (DEHP) accelerate puberty by enhancing testicular androgen synthesis. The current study was designed to determine if the dose response to DEHP was nonmonotonic, as hypothesized. Pubertal administration of DEHP delayed the onset of puberty and reduced androgen-dependent tissue weights in both Long-Evans (LE) and Sprague-Dawley (SD) male rats 300 and 900 mg DEHP/kg/day. These effects were generally of greater magnitude in LE than SD rats. By contrast, alterations in testis histopathology (300 and 900 mg/kg/day) were more severe in SD than in LE rats. Taken together, these results suggest that DEHP may be acting on the pubertal male rat testis via two modes of action; one via the Leydig cells and the other via the Sertoli cells. Treatment with DEHP generally reduced serum testosterone and increased serum luteinizing hormone (LH) levels, demonstrating that the reduction in testosterone was due to the effect of DEHP on the testis and not via an inhibition of LH from hypothalamic-pituitary axis. Testosterone production ex vivo (with and without human chorionic gonadotropin stimulation) was consistently reduced in males at the time of puberty and shortly thereafter. DEHP treatment did not accelerate the age at puberty or enhance testosterone levels at 10 or 100 mg/kg/day in either LE or SD rats, as some have hypothesized. Taken together, these results do not provide any evidence of a nonmonotonic dose response to DEHP during puberty.
Phthalate esters (PEs) are high production volume chemicals used in a variety of consumer products including polyvinyl chloride plastics, toys, personal care products, cosmetics, and pharmaceuticals. Among the PEs, di(2-ethylhexyl) phthalate (DEHP) is the most abundant, with about four million tons of di-octyl phthalates being produced in 1997. This PE is one of several that induce testicular atrophy in the immature male rat after acute or subacute exposure to high dosage levels (Foster et al., 1980) . Research over the last 25 years has shown that some PEs are metabolized to monoesters with an ester side chain of four to six carbons, including benzyl butyl (BBP), dibutyl (DBP), di-iso-butyl, dipentyl, DEHP, dihexyl, and di-iso-heptyl phthalate that induce testicular lesions, including atrophy, Sertoli cell vacuolation, germ cell detachment, and hypospermatogenesis. Although it was first demonstrated in 1985 that the testis of the adult male rat was resistant to the effects of the PE as compared with the young male rat (Sjoberg et al., 1986) , the biological basis for the age-related sensitivity remains unknown. In addition to effects on the testis, rats treated with PEs also often display reduced weights of the seminal vesicle, prostate, and epididymides, and decreased epididymal sperm counts and infertility (Agarwal et al., 1986) . When DBP (Gray et al., 1999) , DEHP (Gray et al., 2009) , or BBP (Nagao et al., 2000) are administered during puberty over a broad dose range, the onset of preputial separation (PPS), a marker of puberty in the male rat, is delayed and androgen-dependent tissue weights are reduced.
More recently, the focus on the reproductive toxicity of the PEs has shifted from reproductive alterations in the young male rat to effects in the fetal male because gestational PE exposures induce male reproductive tract malformations at doses below those that affect the pubertal male rat. During fetal life, PEs disrupt migration and maturation of the fetal Leydig cells (Mahood et al., 2005) , resulting in reduced androgen and insulin-like three peptide hormone levels during sexual differentiation (Wilson et al., 2004) . The reduction in these critical testicular hormones at this stage of development is responsible for disrupted development of the androgen-and insl3-dependent tissues. The fact that the structure-activity-relationship (SAR) for PE-induced reproductive malformations is identical to the SAR for PE-induced testicular atrophy in pubertal male rats (Foster et al., 1980) suggests a common mode of action for the effects of the PEs during both fetal and pubertal life stages. In fact, some of the effects seen with PEs after exposure during fetal or pubertal life are consistent with reduced androgen levels.
Given the preponderance of evidence suggesting that PEs, including DEHP (Gray et al., 2009) , reduce the display of androgen-dependent traits in pubertal male rats, it is surprising that most studies have not found consistent changes in serum testosterone (T) in PE-treated males. It was recently suggested that DEHP treatment increases, decreases or has no affect on serum testosterone depending upon the life stage of treatment initiation, and the duration and dose of treatment (Akingbemi et al., 2001 (Akingbemi et al., , 2004 . Furthermore, Akingbemi et al. (2004) hypothesized that exposure to 10 or 100 mg DEHP/kg during puberty would elevate testosterone and luteinizing hormone (LH) levels and induce precocious puberty in the male rat. They also hypothesized that in females, DEHP exposure would lead to higher estrogen levels, thereby inducing precocious puberty in this gender as well as in the male (Akingbemi et al., 2004) .
In the current study, we conducted two experiments ( Fig. 1 ) to test if peripubertal DEHP treatment would increase testosterone and LH levels and accelerate puberty in the male rat at 10 or 100 mg/kg/day as proposed by Akingbemi et al. (2004) , and if DEHP would delay male rat puberty at higher dosage levels as do BBP (Nagao et al., 2000; Tyl et al., 2004) , DEHP (Gray et al., 2009) and DBP (Ashby and Lefevre 2000; Gray et al., 1999 Gray et al., , 2009 ). The dosage levels of DEHP used in the current study ranged from 10 and 100 mg/kg/day (the dose levels used by Akingbemi et al., 2004) , reported to increase serum T after weaning, up to 900 mg/kg/day, a dose expected to delay PPS. Because Akingbemi and colleagues used LongEvans (LE) rats and most other studies have used SpragueDawley (SD) or SD-derived rats for their pubertal PE studies, we used both LE and SD rats in the first experiment to determine if there were any strain differences in responsiveness to DEHP administered at 10 to 900 mg/kg/day from weaning until 56-98 days of age.
A second experiment was conducted using SD rats, to determine if the serum testosterone (T), ex vivo T production and reproductive organ weights were affected at 43-44 days of age, the age of onset of PPS, and at 63/64 days of age to determine if any DEHP effects on testosterone persisted after PPS. Based upon the results in the first experiment, we expected that 100 mg/ kg/day would be a no observed adverse effect level in the second experiment, and that 300 mg/kg/day would be the lowest observed adverse effect level with minimal effects on androgendependent tissues and T production, with robust alterations at 900 mg/kg/day. We also hypothesized that the reduction in T levels would be more robust at midpuberty during PPS than in adulthood, because several studies have failed to detect alterations in T levels in adult rats treated with PEs during development (Gray et al., 2009) .
Results of the current study demonstrate that DEHP delays puberty at a high dose (900 mg/kg/day) in both LE and SD but does not accelerate pubertal onset at low-dose levels. In the LE rat strain, PPS also was delayed at 300 mg/kg/day. Both LE and SD rats display delays in PPS, although the LE was slightly more affected than was the SD. In contrast to PPS, the testes of the SD males were markedly more affected than were the testes of the LE rat, a strain effect that persisted into adulthood. The delay in PPS in SD rats is accompanied by a decrease in testicular T production. T production was not measured in LE rats.
MATERIALS AND METHODS

General Methods
Animals
Two experiments were conducted to assess effects of peripubertal DEHP exposure on endocrine events and pubertal timing in rats. In the first experiment, LE and SD male rats were purchased from Charles Rivers Laboratory (Raleigh, NC) at 21 days of age. In the second experiment, timedpregnant rats were purchased from Charles River Laboratories and allowed to deliver and the pups were weaned at 21 days of age. Litter sizes were not standardized after birth. Animals were housed in clear polycarbonate cages with laboratory-grade heat-treated pine shavings (Northeastern Products, Warrensburg, NY) with a 14:10-h light/dark photoperiod at 20-24°C and 40-50% relative humidity. Drinking water was available ad libitum and was tested monthly for Pseudomonas and every 4 months for a suite of chemicals, including pesticides and heavy metals. Rat dams and lactating females were fed Purina Lab Chow 5008 (PMI Nutrition International, Richmond, Indiana) ad libitum. Weaned male rat pups and adults were fed Purina Lab Chow 5001 ad libitum. All animal procedures were approved by National Health and Environmental Effects Research Laboratory's Institutional Animal Care and Use Committee.
Doses, Dose Administration, and Experimental Design
Experiment 1
Pubertal effects of DEHP at 0, 10, 100, 300, and 900 mg/kg/day in SD and LE rats. Fifty LE hooded and 50 SD rats (n ¼ 10 per treatment per strain) were weight-ranked and randomly assigned to experimental blocks within strain, such that body weights in all treatment groups had similar means and standard deviations at the start of the study on postnatal day (PND) 22 (Fig. 1) . Laboratorygrade corn oil , cat # C 8267, lot # 81K2204) and DEHP (also called, phthalic acid bis(2-ethylhexyl ester); CAS # 117-81-7, cat # P 6699, lot # 101K3696, listed purity > 99%) were purchased from Sigma (St Louis, MO). Animals were dosed daily with 0, 10, 100, 300, or 900 mg/kg/day DEHP dissolved in corn oil (5 ml/kg until PND 28, 2.5 ml/kg until necropsy). These dosage levels were selected to range from the dose levels used by Akingbemi et al. (2001) (100 mg DEHP/kg/day), who reported that T was occasionally increased after DEHP treatment and therefore would accelerate PPS, to a high dose (900 mg DEHP/kg/ day) that should delay PPS, if DEHP behaved like BBP and DBP.
Male rats were necropsied (n ¼ 6 per group) on PNDs 56-58 and as adults (n ¼ 4 per group on PND 98). Animals were anesthetized by CO 2 asphyxiation and killed by decapitation. Blood was collected for serum hormone analysis.
At necropsy, testes, epididymides, seminal vesicles, levator-ani bulbocavernosus muscles (LABC), liver, kidneys, and adrenals were weighed. All testes, epididymides, and adrenals were preserved in Bouin's fixative for 24 h and then placed in 70% ethanol. Tissues were embedded in paraffin, sectioned and stained with hematoxylin and eosin for microscopic evaluation by a board certified pathologist at Experimental Pathology Laboratories, Inc. (RTP, NC).
Experiment 2
Pubertal effects of DEHP at 0, 100, 300, and 900 mg/kg/day in SD male rats examined at mid-and postpuberty. A second experiment was conducted to examine the effects of DEHP on testis T production ex vivo, serum T and androgen-dependent organs at two ages, mid-and postpuberty. The first cohort was necropsied at the age when the delay in PPS is first evident, and the second cohort was necropsied 20 days later, after PPS is complete, to test if any effects of DEHP on testosterone production and androgen-dependent traits were transient.
Sixty-four male SD rats from litters born in our facility were weight-ranked and randomly assigned to treatments such that body weights of each group had similar means and standard deviations in weaning weight. DEHP was administered at 0, 100, 300, 900 mg/kg/day by gavage in corn oil (5 ml of corn oil or DEHP dose/kg) from PND 23 until PND 37, and with 2.5 ml of corn oil or DEHP dose per kg from PND 38 to necropsy. Males were necropsied on PND 43/44 (8 per group) or at 63/64 (8 per group).
PPS: (a landmark of puberty in the male rat). Beginning on PND 35, male rats were examined (a single observer in each study) for the progression of PPS (detachment of the prepuce from the glans penis) as an index of puberty. In experiment 1, PPS was monitored daily until all rats displayed full PPS, whereas PPS was monitored through PND 43-44 in the second experiment at which time half of the males were necropsied. PPS was scored as stage 1 when it appeared to be initiating, as stage 2 when the prepuce could be retracted about halfway between the point of initial separation and the base of the phallus, and stage 3 when separation was complete (stage 3 being defined herein as ''the age at PPS''). In addition, we also noted if a thread of tissue was present and persisted along the frenulum of the glans.
For experiment 1, the mean age and body weight at PPS were analyzed for DEHP-induced effects using body weight at weaning as a covariate to adjust for size differences that influence age of PPS. We have found that using body weight at weaning (prior to initiation of treatment) eliminates the need to control for litter effects. In experiment 2, the PPS data are presented and analyzed as the proportion of animals separated by 43/44 days of age, because half the animals were necropsied at this stage of life and the age of PPS was not determined.
Evaluation of androgen-sensitive organ weights. Following anesthesia with CO 2 , the body weights of the rats were recorded, and the animals were killed by decapitation. Blood was collected, processed for serum, and stored at -80°C for hormone assays. Androgen-sensitive organs were removed and weighed, including: ventral prostate, seminal vesicles (wet weight), left and right testes and epididymides, LABC muscles, and paired Cowper's glands. If PPS had occurred by the time of necropsy, glans penis was also removed and weighed. Liver, left and right kidney and paired adrenals weights also were measured because some of these are known to be affected by DEHP treatment.
Ex vivo testicular testosterone production. To measure T production ex vivo, one testis from each male rat was decapsulated and sliced into four pieces weighing approximately 75 mg each (methods detailed in Blystone et al., 2007) . The slices were then incubated with or without 100 mIU/ml human chorionic gonadotropin (hCG; Sigma Aldrich) for 1.5 h in 1.5 ml of oxygenated medium 199 with Earle's salts, L-glutamine and without phenol red or sodium bicarbonate (GIBCO Carlsbad, CA), supplemented with sodium bicarbonate (4.4 lM), buffer (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (10mM), and bovine serum albumin (1%) at 34°C. Hormone production was measured using 50 ll of postincubation media in a T radioimmunoassay (RIA) as described below. Samples were run in duplicate, and the values pooled for statistical analysis. Data are expressed as ng T produced per whole testis and ng T produced per mg testis. I-labeled steroids as previously described in Parks et al. (2000) Whole testis T production was determined by dividing the T concentrations measured in media by the fraction of the whole testis (mg of slice/mg of testis) that was incubated.
Serum LH was measured by RIA following iodination preparation I-9, reference preparation RP-3 and antisera S-11 supplied by the National Hormone and Pituitary Agency for LH. Iodination material was radiolabeled with 125 I (Dupont/New England Nuclear) by a modification of the chloramine-T method (Greenwood et al., 1963) . Labeled antigen was separated from unreacted iodide by gel filtration chromatography (Goldman et al., 1986) . Serum samples were brought to a final assay volume of 500 ll with 100mM phosphate buffer containing 1% bovine serum albumin (BSA). Standard reference preparations were serially diluted for standard curves and 200 ll of primary antisera in 100mM potassium phosphate, 76.8mM EDTA, 1% BSA, and 3% normal rabbit serum (pH 7.4) were added to each assay tube, vortexed and incubated at 5°C for 24 h. Iodinated hormone (100 ll) was mixed in each tube and incubated for 24 h, followed by another 24-h incubation using goat anti-rabbit gamma globulin (Calbiochem, San Diego, CA), at a dilution of 1 unit/100 ll). The samples were centrifuged at 1260 3 g for 30 min, the supernatant was aspirated and the sample tube, with pellet, was counted on a gamma counter.
Statistical Analyses
Data were analyzed using the Statistical Analysis System, General Linear Model procedure (SAS Institute Inc., Cary, NC). If the F value was statistically significant, the treatments were further examined using the least squared means test in SAS to compare groups. Statistical significance for main effects was p < 0.05 and p < 0.25 for interactions. For in vivo data, significance for treatment effects on organ weights was determined using an analysis of covariance (ANCOVA) with body weight at weaning as the covariate. Endocrine data were log transformed which corrected for heterogeneity of variance with the standard deviation being proportional to the mean in the untransformed data. The PPS data in the second experiment were analyzed using a Fisher Exact Test which compared the number of males that had and had not attained PPS by 42 days of age in each treated group with the control group.
RESULTS
Experiment 1. LE and SD Rats Necropsied at 56-58 and 98 Days of Age
Age at PPS-Male Rat Puberty
The ages at mid PPS (score 2, representing about 50% PPS) and complete PPS (score 3) were both delayed (p < 0.0001) by DEHP administration at 300 and 900 mg/kg/day in LE rats and at 900 mg/kg/day in SD rats. Complete PPS was delayed longer (strain by treatment interaction (p < 0.1) in the LE (6.6 days) than in the SD rat (3.3 days) at 900 mg DEHP/kg/day (Table 1; Fig. 2 ). Treatment with DEHP at 10 or 100 mg/kg/ day did not accelerate PPS in contrast to the model proposed by others (Akingbemi et al., 2004; Ge et al., 2007) . 
Young (PND 56-58/57) Male Necropsy Results
Androgen-dependent traits were more affected in LE than SD rats (Figs. 3A-H) , with the exception of ventral prostate weights (Table 1) . In contrast, effects on the testis weight (Fig. 3A) and histology, epididymal weight (Fig. 3C) , and sperm counts were considerably more affected in SD than LE rats (Table 1 ; Fig. 4A ). A few reproductive alterations (Table 1) were noted at 100 mg/ kg/day. Most androgen-dependent traits were affected at 300 mg/ kg/day in both LE and SD rats and testis weight was reduced in SD rats at 900 mg/kg/day. Details of the ANOVA are shown on Table 1 . For endpoints displaying significant (p < 0.25) strain by treatment interactions (testis, glans penis, PPS, serum LH), the effects of DEHP differ among LE and SD rats. For endpoints showing no strain by treatment interaction effect, the effect of DEHP is similar among the strains and the pooled means in the tables provide the most parsimonious interpretation of the effects of DEHP (i.e., LABC, Cowper's glands, adrenals, ventral prostate, glans penis, epididymides, and liver). Liver weight was significantly increased by treatment in LE rats at 100, 300, and 900 mg/kg/day (Table 1) . Adrenal gland weights were reduced by DEHP treatment at 300 and 900 mg/kg/day. Compared with LE rats, SD rats had smaller livers, larger ventral prostates, larger Cowper's glands, and larger epididymides at necropsy (Table 1) .
Serum LH was significantly increased at 900 mg/kg/day in SD rats, but there were no significant effects at lower doses (Table 1 ; Fig. 5C ). The increase in LH was not significant in the LE rats. Serum testosterone was reduced by DEHP treatment, but this effect was not significant at any dose Fig.  5A ). Low doses of DEHP did not increase serum testosterone, in contrast to previously proposed hypotheses (Akingbemi et al., 2004) .
Adult male necropsy results in LE and SD rats at 98 days of age. The effects of continued treatment with DEHP on several of the androgen-dependent traits seen in younger males (Table 1, Fig. 3 ) were generally attenuated in the adult males (Table 2, Fig. 3 ).
Testis weights, epididymal weights, and cauda epididymal sperm counts (Fig. 3) were significantly affected in SD rats at 900 mg/kg/day, whereas the LE strain did not display these effects (Table 2, Figs. 4B and C). Testis and epididymal histology were more severely affected in SD than LE rats at both necropsy ages (Table 3) . Testicular effects in LE rats were minimal to mild in severity, whereas the testes of SD males all displayed more severe pathologies. Serum testosterone was reduced in both strains, but this effect was not statistically significant by ANOVA or Dunnett's post hoc test in either strain (Fig. 5B) . Differences detected using a post hoc t-test, suggest that the effect might be significant if a larger number of animals had been sampled. Serum LH was significantly increased in SD, but not LE rats (Table 2 ; Fig. 5D ). DEHP increased liver weight at 100 mg/kg/day and above in LE rats, and at 900 mg/kg/ day in SD rats (Table 2) . Compared with LE rats, SD rats at 98 days of age had significantly heavier ventral prostates and LABC muscles at necropsy.
Testicular and epididymal histopathology in PND 56/58 and PND 98 LE and SD male control and DEHP-treated rats. The lesions of the testis and epididymides (Table 3) reflected the changes seen in testes weights. LE rats displayed testis and epididymal lesions at 300 and 900 mg/kg/day, but these lesions were far less prevalent and less severe than those seen in SD rats (Table 3) . Severe histopathological testis and epididymal lesions (category 5) or azoospermia were seen only in SD male rats. The testes of LE rats were either unaffected or displayed minimal (category 1) or mild (category 2) histopathological lesions. Testicular and epididymal histopathological lesions in the SD rat were as prevalent and severe at 98 days of age as they were at 57 days of age. In contrast, the histopathological alterations of the testis of LE male rats were attenuated with age. In LE rats, only a single minimal testis lesion (1/4 PND 98 males affected) was detected, whereas 3/6 males displayed testicular degeneration at PND 57.
Results of Experiment 2. SD Rats Necropsied at 43/44 and 63/64 Days of Age
Age at PPS-Male Rat Puberty PPS data from males treated from PND 23 were collected up to 42 days of age, when half the animals were necropsied. Data were analyzed using Fisher's exact test, comparing the numbers of males displaying PPS in each treated to the control group (Fig. 6) . Treatment with 900 mg DEHP/kg/day lowered the percentage of animals attaining PPS by 42 days of age (Fig. 6) . The data could not be analyzed using the mean age at PPS because half the males were necropsied at 42 days of age, prior to the completion of PPS in the population. As in experiment 1, PPS was not altered at 10 or 100 mg/kg/day, again failing to support the hypothesis that DEHP at low doses accelerated the age at puberty (Akingbemi et al., 2004) . Gavage from Weaning to Necropsy Experiment 1. Testicular and epididymal histopathology Rat strain 0 mg/kg/day 10 mg/kg/day 100 mg/kg/day 300 mg/kg/day 900 mg/kg/day Testicular degeneration Postpubertal LE 0/6, 0% 0/6, 0% 0/6, 0% 1/6 (1), 17% 3/6 (1-2), 50% SD 0/6, 0% 0/6, 0% 0/6, 0% 2/6 (1), 33% 6/6 (3-5), 100% Adult LE 0/4, 0% 0/4, 0% 0/4, 0% 0/4, 0% ¼ (1), 25% SD 0/4, 0% 0/4, 0% 0/4, 0% ¼ (1), 25% 4/4 (2-5), 100% Epididymal germinal epithelial degeneration Postpubertal LE 0/6, 0% 0/6, 0% 0/6, 0% 1/6 (1), 17% 6/6 (2-3), 100% SD 0/6, 0% 0/6, 0% 0/6, 0% 2/6 (1), 33% 5/6 (1-3), 83% Adult LE 0/4, 0% 0/4, 0% 0/4, 0% 0/4, 0% 0/4, 0% SD 0/4, 0% 0/4, 0% 0/4, 0% 0/4, 0% ¼ (1), 25% Epididymal hypospermia or aspermia Postpubertal LE 0/6, 0% 0/6, 0% 0/6, 0% 1/6 (1), 17% 6/6 (2-4), 100% SD 0/4, 0% 0/4, 0% 0/4, 0% 3/6 (2-3), 50% 6/6 (4-5), 100% Adult LE 0/4, 0% 0/4, 0% 0/4, 0% 0/4, 0% 0/4, 0% SD 0/4, 0% 0/4, 0% 0/4, 0% 0/4, 0% (2), 75%
Note. Shaded areas differ significantly from control values. Values are number affected/number observed (severity or severity range), % affected. Severity key: 1 ¼ minimal; 2 ¼ slight/mild; 3 ¼ moderate; 4 ¼ moderately severe; 5 ¼ severe/high. Shaded areas are affected groups, whereas the darker shading identifies groups with animals displaying more severe lesions. Body (900 mg/kg/day), adrenal (100 mg/kg/day and above) seminal vesicle (300 and 900 mg/kg/day; Fig. 7C ), testis (300 and 900 mg/kg/day), Cowper's glands (100 mg/kg/day and above; Fig. 7G ), epididymides (900 mg/kg/day) and LABC (300 and 900 mg/kg/day; Fig. 7E ) weights were significantly reduced by DEHP treatment (Table 4) . DEHP treatment increased liver weights at 100 mg/kg/day and above. Histopathological analyses were not conducted in this experiment for either age group.
DEHP REDUCES TESTOSTERONE AND DELAYS MALE RAT
Serum and ex vivo testosterone production and serum LH at 43/44 days of age in male SD rats. Serum testosterone at 43/44 days tended to decrease (Fig. 8A ), but the effect was not statistically significant (Table 4) . Serum LH was significantly increased at 900 mg/kg/day (Fig. 8C) . Ex vivo testosterone production by the minced testis pieces, either with or without hCG stimulation, displayed a significant decrease at 300 and 900 mg/kg/day (Fig. 9) . Figure 9A displays all the data as percent of control. In Figure 9B the data were fit to a logistic regression curves to show that testosterone production was affected to the same degree with or without hCG stimulation. Figures 9C and D display the effects of DEHP on testosterone production in ng/ml, showing that the testosterone production per testis is much higher in 63/64 old males (D) than in 44-day-old males. These endocrine results are less variable indicators of the androgenic status of the male rat than is serum testosterone because the hormone levels in the serum are highly variable being released from the testes into the bloodstream in large pulses. None of these endocrine measures displayed a nonmontonic dose response; neither endocrine measure increased at 100 mg/kg/day as proposed in the model of Akingbemi et al. (2004) .
Necropsy Data from Postpubertal 63/64-Day-Old Male SD Rats
Testis (900 mg/kg/day), epididymides (300 and 900 mg/kg/ day), ventral prostate (900 mg/kg/day) (Fig. 7B) , seminal vesicle (900 mg/kg/day) (Fig. 7D) , glans penis (900 mg/kg/ day), Cowper's (900 mg/kg/day) (Fig. 7H) , and LABC (300 and 900 mg/kg/day) (Fig. 7F) weights were significantly reduced. Liver weights were increased at 100 mg/kg/day and above (Table 4) .
Serum and ex vivo testosterone production and serum LH at 63/64-day-old SD rats. Serum testosterone was not reduced by DEHP treatment (Fig. 8C) , whereas serum LH was increased at 900 mg/kg/day (Fig. 8D) . Ex vivo testicular testosterone production per testis was significantly reduced at 900 mg DEHP/kg/day in SD male rats at 63/64 days of age. In contrast, ex vivo testicular testosterone was suppressed at both 300 and 900 mg DEHP/kg/day at 43/44 days of age (Fig. 9) .
DISCUSSION
In the current study, pubertal administration of DEHP by gavage delayed the onset of puberty and transiently reduced androgen-dependent tissue weights in both LE and SD male rats. Although the lowest dose of DEHP examined in the current study (10 mg/kg/day) did not induce any changes in reproductive endpoints, it did increase liver weights in young LE rats. Subtle changes were seen in some androgen-dependent organ weights at 100 mg/kg/day in young males. Testis histology was altered at 300 and 900 mg/kg/day in both LE and SD rats, however, the SD strain was more severely affected. Puberty was delayed in LE male rats at 300 and 900 mg/kg/day and at 900 mg/kg/day in SD male rats.
Treated males generally displayed reduced serum testosterone levels, but this endpoint was highly variable (Fig. 10 ) which likely resulted from the pulsatile release of this hormone from the testis into the serum (Steiner et al., 1984) . Ex vivo testosterone production (with and without hCG stimulation) was a more precise measure of the androgenic status of the males, being clearly reduced in DEHP-treated males at the acquisition of puberty (PPS) and shortly thereafter. Serum LH levels were generally increased at all ages, demonstrating that the reduction in testosterone was due to a direct effect of DEHP on the testis and not via alterations of the hypothalamicpituitary-gonadal axis. If the effect of DEHP on testosterone production was mediated via the hypothalamic-pituitarygonadal axis then LH levels would be decreased rather than increased by DEHP treatment.
The results of the current study provide no evidence for nonmonotonic dose responses to subchronic DEHP administration and are consistent with the effects of DEHP administered continuously from early pregnancy through puberty (Gray et al., 2009) . Furthermore, treatment with DEHP did not accelerate the age at puberty nor did DEHP treatment enhance testosterone levels at low doses (10-100 mg/kg/day) in either LE or SD rats as some have hypothesized (Akingbemi et al., 2001; Ge et al., 2007) . In contrast, higher DEHP dose levels consistently delayed puberty and inhibited the development of other androgendependent traits by reducing testis testosterone production. Akingbemi et al. (2004) and Ge et al. (2007) proposed that DEHP had a biphasic effect on the onset of puberty with low doses accelerating the onset of PPS and increasing serum androgen levels (Table 5) . Ge et al. (2007) reported that DEHP at 10 mg/kg/day accelerated the onset of PPS in LE rats. Akingbemi et al. (2004) administered DEHP at 10 and 100 mg/ kg/day from 21 to 90 and 21 to 120 days of age to LE male rats. At 90 days of age, serum testosterone was reported to increase from about 2.9 ng/ml in controls to 5.3 and 4.2 at 10 and 100 mg/kg/day, respectively and at 120 days of age, serum testosterone was reported to increase from about 6.2 ng/ml in controls and 6.3 at 10 mg/kg/day to 9.5 ng/ml at 100 mg/kg/ day (Akingbemi et al., 2004) . In our first experiment we were unable to replicate this increase in serum testosterone at 10 or 100 mg/kg/day in either the LE or SD rat at any age, including: 43/44, 56-58, 63/64, or 98 days of age. We also found that DEHP administration did not accelerate puberty at low (10 and 100 mg/kg/day) doses as proposed by Akingbemi et al. (2004) .
Instead, we found that DEHP delays puberty at 300 and 900 mg/kg/day in LE rats and the delay in PPS, is associated with transient mid-pubertal reductions in serum testosterone and testis testosterone production. In addition, we did not detect any nonmontonic dose response relationships on any reproductive endpoint in the current study.
In multigenerational studies, administration of PEs during puberty also delays PPS in male rats at high dose levels, whereas low doses are without effect. For example, chronic dietary administration of BBP at 20 and 100 mg/kg/day had no affect on the age at PPS whereas treatment with 500 mg/kg/day delayed PPS in SD male rats (Nagao et al., 2000; Tyl et al., 2004) . Similarly, dietary administration of DBP during gestation, lactation and after weaning delayed PPS at 50 mg/ kg/day in LE rats (Salazar et al., 2004) . Administration of DBP by oral gavage after weaning also delays PPS in both LE and SD male rats (Gray et al., 1999) Note. Shaded areas differ significantly from control values as determined by LSMEANS (t-test) following a significant F value by ANOVA using PROC GLM on SAS 9.1. *p < 0.05,**p < 0.01, Agency, Endocrine Disruptor Screening Program web site; http://www.epa.gov/endo/pubs/block1_trc_fr_100.pdf; last accessed May 24, 2009). In addition, we have found that administration of DEHP in utero, during lactation and through puberty to SD male rats at 11, 33, 100, and 300 mg/kg/day delays puberty at 300 mg/kg/day, with no effect on PPS at lower doses (Gray et al., 2009) . Taken together, these results indicate that PEs like DEHP, BBP, and DBP that disrupt testis function via a common mode(s) of action do not disrupt puberty in the rat in a biphasic manner; they delay male rat puberty at high doses with no effect at lower doses (10-100 mg/kg/day).
Although we were not surprised by observations that DEHP delayed puberty or decreased testosterone levels in the LE or the SD rat, we did not expect to see such large differences in the testicular effects of DEHP administration in the LE versus the SD rat strains. The effects of DEHP in the LE male rats were less robust than those seen in a multigenerational study with another phthalate DBP using this rat strain (Gray et al., 1999) . In the earlier study, administration of DBP at 250, 500, and 1000 mg/kg/day from weaning through puberty, young adulthood and mating through necropsy (at about 100 days of age) reduced testis weight by about 75% relative to control values. Testis and epididymal sperm counts were reduced by more than 99% of controls, and the DBP-treated males were infertile. At 500 mg DBP/kg/day, three of eight males were infertile with testis weights and sperm counts reduced by 50 and 75% of control values, respectively; whereas, testis weights and sperm counts were relatively normal in the remaining five males (Gray et al., 1999) . In the current DEHP study, the testes weight and histology of the LE male rats were considerably less affected than were the testes of the SD rats. The testes of the SD rats in the 900 mg/kg/day group were severely affected at midpuberty and this effect was still evident until 98 days of age. In contrast, in the LE rat testes appeared minimally affected at midpuberty and these effects did not persist, even with continuous dosing until 98 days of age. This is not the first case in which DEHP has been shown to differentially affect the developing reproductive system in different strains of rats, although the other reports used in utero exposures. Wilson et al. (2007) found that exposure to PEs during sexual differentiation produced striking differences seen in the incidences of epididymal (67% in SD vs. 8% in Wistar) and gubernacular lesions (0% in SD vs. 64% in Wistar) between SD and Wistar male rats. They proposed that the different malformation profiles produced by in utero phthalate treatment arose, in part, from strain differences in fetal Leydig cell function and the manner in which these cells respond to DEHP treatment.
We also did not expect to detect a strain difference in the effect of DEHP on the age at puberty (PPS). However, DEHP treatment at 900 mg/kg/day produced a significantly longer delay in PPS in the LE rat than it did in the SD rat. The delays in PPS seen in the current study with 300 and 900 mg DEHP/kg/day are very similar to those seen previously with DBP at 250 and 1000 mg/ DEHP REDUCES TESTOSTERONE AND DELAYS MALE RAT PUBERTY kg/day (Gray et al., 1999) . In addition, several other androgendependent traits were more affected in LE than SD rats.
In conclusion, results of the current study show that pubertal exposure to DEHP reduces testosterone production resulting in delays in the onset of PPS, a landmark of puberty in the male rat, and reduces androgen-dependent reproductive organ weights.
Low doses of DEHP did not cause increases in serum testosterone or accelerate puberty in either LE or SD rats. As expected, DEHP also affected testis histology and weights. The striking difference in the severity of the testicular lesions seen between the two strains, with the treated SD rats being more severely affected than LE rats, was not expected, especially because it appeared that the effects of DEHP on the androgen signaling pathway were greater in LE than SD rats, as evidenced by the high dose effects of DEHP on the age at PPS. Taken together, the observation that DEHP treatment during puberty differentially affects testosterone production and testis histology in the two rat strains suggests that DEHP may be acting on the pubertal male rat testis via two modes of action; one via direct effects on the Leydig cells and testosterone production and the other via the Sertoli cells and maintenance of the germ cells. 
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FIG. 10.
Effects of oral DEHP on the serum testosterone levels in male LE and SD rats from both experiments (43/44, 56-58, 63/64, and 98-day-old SD male rats and 56-58 and 98-day-old LE male rats), treated from weaning until necropsy. 
